PERBANDINGAN ANTARA PEMBERIAN REMDESIVIR DAN FAVIPIRAVIR TERHADAP LAMA RAWAT INAP PASIEN COVID-19
Abstract
Coronavirus disease 2019 (COVID-19) merupakan salah satu masalah kesehatan masyarakat global yang diperkirakan memiliki progresivitas penyakit parah dan memerlukan rawat inap. Terapi farmakologik berupa antivirus yang dianjurkan dalam buku panduan tatalaksana COVID-19 di Indonesia adalah remdesivir dan favipiravir. Tujuan terapi farmakologik adalah untuk memperbaiki klinis pasien yang dirawat inap yang keberhasilannya dapat diukur melalui durasi atau lama rawat inap. Tujuan penelitian ini adalah untuk mengetahui bagaimana perbandingan antara pemberian terapi remdesivir dan favipiravir terhadap lama rawat inap pasien COVID-19. Desain penelitian adalah cross-sectional dengan sampel 42 rekam medis pasien didiagnosis COVID-19 yang dirawat inap selama periode Mei sampai dengan November 2021. Hasil penelitian menunjukkan terdapat perbedaan bermakna antara pemberian remdesivir dan favipiravir terhadap lama rawat inap pasien COVID-19 (p<0,05). Rerata lama hari rawat inap pasien COVID yang menerima terapi favipiravir lebih singkat yaitu 7,33 ± 1,983 (mean ± SD) dibandingkan remdesivir yaitu 9,29 ± 1,927 (mean ± SD). Kesimpulan dari penelitian ini adalah favipiravir lebih efektif dibandingkan remdesivir dalam mengurangi lama rawat inap pasien COVID-19 yang sesuai dengan kriteria pada penelitian ini.
Kata kunci: COVID-19, favipiravir, lama rawat inap, remdesivir
DOI : 10.35990/mk.v7n1.p57-67
References
2. Mudenda S, Witika BA, Sadiq MJ, Banda M, Mfune RL, Daka V, et al. Self-medication and its consequences during & after the Coronavirus Disease 2019 (COVID-19) Pandemic: A Global Health Problem. Eur J Environ Public Health. 2020 Nov 30;5(1):em0066.
3. Yetmar ZA, Issa M, Munawar S, Burton MC, Pureza V, Sohail MR, et al. Inpatient care of patients with COVID-19: A guide for hospitalists. Vol. 133, American Journal of Medicine. Elsevier Inc.; 2020. p. 1019–24.
4. Kementerian Kesehatan Republik Indonesia. Situasi terkini perkembangan COVID-19 [Internet]. Jakarta; 2022 Jul. Available from: https://covid19.who.int/data.
5. Burhan E, Dwi Susanto A, Isbaniah F, Aman Nasution S, Ginanjar E, Wicaksono Pitoyo C, et al. Pedoman Tatalaksana COVID-19 Edisi 4. 2020.
6. Hachfi W, ben Lasfar N, Wissem Hachfi C. COVID-19: Main therapeutic options. Vol. 98, LA TUNISIE MEDICALE. 2020.
7. Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: The reality and challenges. Vol. 53, Journal of Microbiology, Immunology and Infection. Elsevier Ltd; 2020. p. 436–43.
8. Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, et al. Role of favipiravir in the treatment of COVID-19. Vol. 102, International Journal of Infectious Diseases. Elsevier B.V.; 2021. p. 501–8.
9. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: An Open-Label Control Study. Engineering. 2020 Oct 1;6(10):1192–8.
10. McFee RB. COVID-19: Therapeutics and interventions currently under consideration. Vol. 66, Disease-a-Month. Mosby Inc.; 2020.
11. World Health Organization. Guideline therapeutics and COVID-19: living guideline [Internet]. 2022. Available from: http://apps.who.int/bookorders.
12. Dyussenbayev A. Age periods of human life. Adv Soc Sci Res J. 2017 Mar 25;4(6).
13. Amber L. Mueller, Maeve S. McNamara, David A. Sinclair. Why does COVID-19 disproportionately affect older people? Aging. 2020;12(10).
14. Damayanti H, Sajinadiyasa IGK, Risni HW, Sauriasari R. The Effectiveness and safety of favipiravir in COVID-19 hospitalized patients at Tertiary Referral Hospital, Bali,Indonesia. Kesmas. 2021 Nov 1;16(4):289–97.
15. Taslem Mourosi J, Anwar S, Hosen MJ. The sex and gender dimensions of COVID-19: A narrative review of the potential underlying factors. Vol. 103, Infection, Genetics and Evolution. Elsevier B.V.; 2022.
16. Çalik Başaran N, Uyaroğlu OA, Tellı Dızman G, Özişik L, Şahın TK, Taş Z, et al. Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU. Turk J Med Sci. 2021;51(2):411–20.
17. Negru PA, Radu AF, Vesa CM, Behl T, Abdel-Daim MM, Nechifor AC, et al. Therapeutic dilemmas in addressing SARS-CoV-2 infection: favipiravir versus remdesivir. Vol. 147, Biomedicine and Pharmacotherapy. Elsevier Masson s.r.l.; 2022.
18. Simonis A, Theobald SJ, Fätkenheuer G, Rybniker J, Malin JJ. A comparative analysis of remdesivir and other repurposed antivirals against SARS‐CoV‐2. EMBO Mol Med. 2021 Jan 11;13(1).
19. WHO Solidarity Trial Consortium. Repurposed antiviral drugs for COVID-19 — Interim WHO solidarity trial results. New England Journal of Medicine [Internet]. 2021 Feb 11;384(6):497–511. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2023184
20. Yamamura H, Matsuura H, Nakagawa J, Fukuoka H, Domi H, Chujoh S. Effect of favipiravir and an anti-inflammatory strategy for COVID-19. Vol. 24, Critical Care. BioMed Central; 2020.
21. Łagocka R, Dziedziejko V, Kłos P, Pawlik A. Favipiravir in therapy of viral infections. Vol. 10, Journal of Clinical Medicine. MDPI; 2021. p. 1–16.
